Epizyme reported $-35744000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Abbott ABT:US $ 2973M 926M
Agios Pharmaceuticals AGIO:US $ -91.81M 2.97M
Amarin AMRN:US $ -64.8M 36.45M
Biogen BIIB:US $ 874.8M 28.6M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Cerulean Pharma CERU:US $ -8.4M 1.14M
Daiichi Sankyo 4568:JP Y 29415M 81785M
Eisai 4523:JP Y 9722M 30501M
Epizyme EPZM:US $ -35.74M 19.73M
Exelixis EXEL:US $ 88.51M 3.28M
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Macrogenics MGNX:US $ -41.3M 25.14M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Novartis NOVN:VX SF 4129M 217M
Novartis NVS:US $ 4129M 217M
Spectrum Pharmaceuticals SPPI:US $ -29.03M 13.65M
Xencor XNCR:US $ -33.98M 57.57M